Hormonal Contraception and Depression: Updated Evidence and Implications in Clinical Practice Franca FruzzettiTiziana Fidecicchi Review Article 27 September 2020 Pages: 1097 - 1106
Performance-Based Risk-Sharing Arrangements (PBRSA): Is it a Solution to Increase Bang for the Buck for Pharmaceutical Reimbursement Strategy for Our Nation and Around the World? Andy Eunwoo KimDavid Hohyun ChoiSean Hyungwoo Kim Review Article 09 October 2020 Pages: 1107 - 1113
Treatment of Major Depressive Disorder in Japanese Patients with Cancer: A Matched Cohort Study Using Employer-Based Health Insurance Claims Data Tatsuo AkechiShinji FujimotoKatsuhito Murase Original Research Article Open access 18 October 2020 Pages: 1115 - 1125
Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus Zhenling YaoLaura LoggiaZhenhua Xu Original Research Article 21 October 2020 Pages: 1127 - 1136
Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis Yitian LangDeshi DongBin Wu Original Research Article 23 October 2020 Pages: 1137 - 1146
Data Mining for Adverse Events of Tumor Necrosis Factor-Alpha Inhibitors in Pediatric Patients: Tree-Based Scan Statistic Analyses of Danish Nationwide Health Data Viktor WintzellHenrik SvanströmMartin Kulldorff Original Research Article Open access 26 October 2020 Pages: 1147 - 1154
Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study Shuai ZhengFeng ShaoTao Yang Original Research Article 30 October 2020 Pages: 1155 - 1166
Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia Masnoon SaiyedJoshua ByrnesMartin Downes Original Research Article 02 November 2020 Pages: 1167 - 1176
Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors Alessandra SerraoEmilia ScalzulliAntonio Chistolini Short Communication 22 October 2020 Pages: 1177 - 1181